Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Colorcon
Chinese Patent Office
Citi
Argus Health
US Department of Justice
QuintilesIMS
Moodys
Express Scripts

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,759,316

« Back to Dashboard

Summary for Patent: 8,759,316
Title:Maintenance of platelet inhibition during antiplatelet therapy
Abstract: A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.
Inventor(s): Ruderman Chen; Lisa (Rye, NY), Skerjanec; Simona (Basel, CH), Bell; Dawn (Morristown, NJ), Prats; Jayne (Carlisle, MA), Todd; Meredith (Hoboken, NJ), Arculus-Meanwell; Clive Arthur (Bernardsville, NJ), Mould; Diane (Fort Meyers, FL)
Assignee: The Medicines Company (Parsippany, NJ)
Application Number:13/931,384
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,759,316

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Chiesi Usa Inc KENGREAL cangrelor POWDER;IV (INFUSION) 204958-001 Jun 22, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,759,316

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,871,736 Maintenance of platelet inhibition during antiplatelet therapy ➤ Try a Free Trial
8,680,052 Methods of treating, reducing the incidence of, and/or preventing ischemic events ➤ Try a Free Trial
9,427,448 Methods of treating, reducing the incidence of, and/or preventing ischemic events ➤ Try a Free Trial
9,320,754 Maintenance of platelet inhibition during antiplatelet therapy ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,759,316

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009246396 ➤ Try a Free Trial
Australia 2010319612 ➤ Try a Free Trial
Australia 2012295343 ➤ Try a Free Trial
Australia 2013381855 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Julphar
US Army
Colorcon
UBS
Federal Trade Commission
Boehringer Ingelheim
Baxter
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.